Tisotumab vedotin is an investigational antibody-drug conjugate targeted to tissue factor.
The phase 3 trial evaluated the efficacy and safety of cemiplimab in women 18 years of age and older with recurrent or metastatic cervical cancer, including those with either squamous cell carcinoma or adenocarcinoma.
Association between delay and increased mortality significant for 13 of 17 indications.
Results of a large cohort study investigated sources of iatrogenic and noniatrogenic injuries in women coping with a potential diagnosis of cervical cancer.
Incidence rate ratio 0.12 among women vaccinated before age 17; 0.47 for those vaccinated at ages 17 to 30.